Want to join the conversation?
$BAX's sales within the U.S. for 4Q15 rose 1% to $1.1Bil, while international sales totaled $1.5Bil, representing a 2% increase on a constant currency basis, and 12% decline on a reported basis. Adjusting for impact of FX and generic market entrant in the U.S. for its oncology injectable, cyclophosphamide, $BAX's global sales rose 4%.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.